35 results about "Cd4 cell" patented technology

A microchannel chip for counting floating microparticles with an optical method is provided. The depth of the microchannel chip is made to be a depth of field such that a clear and sharp optical image of microparticles can be obtained, without necessarily diluting the microparticle mixture inside the microchannel. Consequently, a microparticle counting instrument can easily count microparticles shown on an optical image of the microchannel. Particularly, it enables to count more easily the number of CD3 cells CD4 cells or CD8 cells in white blood cells being stained, without lysing or diluting red blood cells. Therefore, the microchannel chip can advantageously used for counting the number of CD3 cells, CD4 cells or CD8 cells in blood of an AIDS patient to monitor the progression of AIDS.

Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.

The invention provides a CD4 protein-resistant monoclonal antibody and an active fragment and an application thereof. The antibody can be used for preventing a human immunodeficiency virus (HIV) from invading cells through combination with a human CD4 protein. The antibody can be used for detecting, diagnosing, preventing and treating diseases in which CD4 cells are taken as target cells, particularly an acquired immunodeficiency syndrome caused by the HIV. The invention further provides a relevant hybrid tumor cell strain, a separated nucleic acid molecule, a small peptide, a medicinal composition comprising the monoclonal antibody, and a kit.

The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies utilized to treat infectious agents have not been adequate to contain and eradicate this deadly viral infection. HIV seeks out its host, a T-Helper cell, by utilizing glycoprotein 120 probes to engage a CD4 cell-surface receptor located on the surface of a T-Helper cell. Developing blood filtering techniques that incorporate filter mediums that offer HIV virion's probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing and removing HIV. Filtering the blood of a patient with filter mediums comprised of T-Helper cells, sheets of lipid bilayer or virus-like structures with each type of medium possessing cell-surface receptors intended to attract and engage HIV virions provides an effective strategy to prevent and treat AIDS.

The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and/or transplantation.

Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV) infection into a nonserious disease through the infusion of monoclonal antibodies directed against particular antigens on anti-self, anti-CD4 cytotoxic T-lymphocytes. The monoclonal antibodies are primarily directed against the alpha or beta chain of LFA-1.

The invention relates to the field of tumor cellular immunotherapy, in particular to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises a hinge region, and the hinge region is IgG4-CH3. The IgG4-CH3 hinge region is introduced into a CAR molecular structure, so that the amplification efficiency of CAR T cells can be specifically increased in an in-vitro culture process, the amplification of CD4+CAR T cells is mainly promoted, CD4 cells and CD8 T cells do not need to be cultured in a separated way, the process is completed in a mixing system, and the amplification efficiency of the CD4+CAR T cells is increased.

This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-I to the subject's CCR5CD4 cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The invention discloses a CD4 (Cluster of Differentiation 4) cell chip which comprises a solid phase support and an antibody fixed on the support, wherein the antibody is a CD4 monoclonal antibody, and the solid phase support is a slide. The invention also discloses a preparation method of the CD4 cell chip, a CD4 cell assay kit containing the CD4 cell chip and a method for applying the CD4 cell chip to detection. The invention also discloses the application of the CD4 cell chip and the CD4 cell assay kit. The CD4 cell chip has the advantages of low cost and simple and convenient operation and is especially applicable to poverty-stricken zones seriously infected by AIDS viruses.

The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.

The invention discloses application of Chi3l1 in regulation and control of immune regulation effect of human umbilical cord mesenchymal stem cells, wherein the immune regulation effect is to inhibit Th17 cell differentiation. By use of the transcriptome data of mesenchymal stem cells derived from early-stage human bone marrow, amnion, placenta and umbilical cord, bioinformatics analysis finds that the umbilical cord mesenchymal stem cells highly express Chi3l1 and are subjected to regulatory expression by main inflammatory factors IFN-[gamma] and TNF-[alpha]. An in-vitro human umbilical cord mesenchymal stem cell and T cell co-culture experiment finds that Chi3l1 can regulate and control the Th17 cell differentiation inhibition effect of the human umbilical cord mesenchymal stem cells, after Chi3l1 is knocked down, a Th17 cell differentiation inhibition capacity is reduced, meanwhile, p-STAT3 expression of CD4 cells is increased, and after a p-STAT3 inhibitor (S3I-201) is added, the Th17 differentiation inhibition capacity of hUC-MSCs is recovered.

The invention discloses an HIV antiviral statistical analysis method based on a Bayesian model. The method comprises the following steps: constructing a partial linear model under a Bayesian quantileregression method according to a collected data set, and acquiring clinical indexes closely related to disease progression; constructing a hierarchical change point model under a finite hybrid framework according to the data set; and performing posteriori simulation on the hierarchical change point model under the finite hybrid framework to obtain joint posteriori distribution of the observation data. According to the method, a hierarchical change point finite hybrid model taking CD4 cell counting as a response variable is established, so that the heterogeneity presented by CD4 cell mean valuetrajectories among different individuals after treatment can be reasonably described, and the relationship between the drug curative effect and time is further explored; and based on the model, intervention treatment schemes suitable for anti-HIV virus treatment of different individuals can be developed, and research on a clinical diagnosis and treatment scheme cost effect evaluation model is carried out.

The invention provides an oral liquid for controlling HIVs (human immunodeficiency viruses) and a preparation method of the oral liquid. The oral liquid for controlling the HIVs comprises a component I and a component II, wherein the component I is prepared from raw materials in parts by weight as follows: 20-55 parts of fragrant eupatorium herbs, 35-45 parts of trichosanthes roots, 15-18 parts of scorpions, 8-15 parts of centipedes, 22-32 parts of garter snakes, 25-35 parts of white peony roots, 35-45 parts of danshen roots, 15-45 parts of Siberian cocklebur fruits and 500-750 parts of rice wine; the component II is prepared from raw materials in parts by weight as follows: 35-70 parts of daylily roots, 20-55 parts of tortoise plastron and 400-500 parts of rock candy. All the traditional Chinese medicines are combined for use and complement one another, copy propagation of the HIVs in a patient body can be effectively controlled, the number of CD4 cells in the patient body can be increased to be at the normal level, and the body immunity is enhanced; the preparation method of the oral liquid for controlling the HIVs is simple, and the oral liquid is small in toxic and side effects, easy to produce, low in cost and beneficial to energetic popularization.

Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

The present invention is extracorporeal cell culture model and process for HIV-1 infected CD4+ cell, and relates to life science and medicine field. The present invention provides comprehensive HIV-1 infection treating mechanism for curing HIV-1 infection radically, designs new HIV-1 antagonizing medicine, provides new detection mechanism for detecting HIV-1 infection treating medicine, and provides relevant experiment reference. The present invention may be used in screening new HIV-1 antagonizing medicine for curing AIDS in early stage radically.

The invention discloses a medicine for assisting in treating acquired immune deficiency syndrome and a preparing method thereof. The preparing method includes the steps that 1, 20-30 parts by weight of raw radix astragalis, 15-20 parts by weight of burdock roots and 10-15 parts by weight of roots of soulie barberry are respectively taken, soaked, carefully selected, cleaned and dried, the burdock roots, the roots of soulie barberry and distilled water are weighed in the weight ratio of 200:50:1000 and jointly decocted for 1 h to 2 h, the decocting-extracted liquid medicine is filtered with a 50-70-mesh screen, and filtered liquid is obtained; 2, the filtered liquid obtained in the step 1 is concentrated to be 1.25 to 1.35 in relative density, and concentrated liquid is obtained; 3, 20-30 parts by weight of raw radix astragalis powder are added into the concentrated liquid obtained in the step 2, the mixture is mixed to be even, and the medicine for assisting in treating acquired immune deficiency syndrome is obtained. The medicine has obvious effects in the aspects of repairing CD4 cells of a patient, improving the immunity of the patient, improving disease resistance, prolonging the lifetime of the acquired immune deficiency syndrome patient, improving the living quality of the acquired immune deficiency syndrome patient and the like.

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

The invention relates to methods for the treatment and/or prophylaxis of infections that produce an imbalance of Th1 and Th2 CD4 cells such as Leishmaniasis, via the administration of an antibody to IL-9 or an agent that stimulates production of anti-IL-9 antibodies sufficient to neutralize native IL-9 in a subject.

The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies utilized to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by having utilizing glycoprotein 120 probes to engage CD4 cell-surface receptors located on the surface of a T-Helper cell. Development of protective barrier techniques for women to utilize during sex that incorporate filter mediums that offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. Providing barriers with filter mediums comprised of sheets, strips, or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed cell-surface receptors intended to engage HIV virions provides an effective strategy to prevent AIDS in women.

A method of inhibiting an immune response mediated by one or more of TLR2, RAGE, CCR5, CXR4 and CD4 cell surface receptors of cells in recognized need is disclosed. The method contemplates administering to such cells an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) whose structure is defined within. In one embodiment, the cells to which the compound or its salt is administered exhibit a hyperinflammatory syndrome.

Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

The invention provides application of an ingenol compound and a derivative thereof in anti-HIV treatment, and in particular provides application of an ingenol compound or pharmaceutically acceptable salts thereof. The ingenol compound or the pharmaceutically acceptable salts thereof can be used for (a) interfering HIV latency; (b) inhibiting HIV infection; and/or (c) reducing the expression of a CD4 cell HIV infected surface receptor. When the compound provided by the invention is used in combination with an AIDS therapeutic agent (such as an anti-retroviral drug, an immunomodulator, a therapeutic antibody or a combination thereof), the elimination of a latent virus reservoir can be accelerated; and the cure rate of AIDS can be easily improved.